-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US36870G1058 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Target Price | 1.5 |
| Dividend Yield | 0.0% |
| Beta | -0.12 |
| Market Cap | 58M |
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GMTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025